Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 in Pediatric and Adult Patients With Recurrent or Refractory Medulloblastoma and Other Tumors
NCT01125800Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2011
- Primary completion
- Oct 2014
- Modality
- Allosteric Modulators
- Countries
- 6
01
Overview
Phase 2, open-label trial of sonidegib in medulloblastoma, rhabdomyosarcoma (RMS), neuroblastoma and 4 more (5 arms), sponsored by Novartis. Primary endpoints: Dose-limiting Toxicities at Day 42, Maximum Tolerated Dose at Day 42 and 1 more. Started Feb 2011; status: completed.
02
Drugs
sonidegib
03
Conditions
medulloblastomarhabdomyosarcoma (RMS)neuroblastomahepatoblastomaglioma
Beyond the preview
Go deeper on NCT01125800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125800.